Yervoy/Nivolumab Combo Keying Bristol’s Immuno-Oncology R&D Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
At the Morgan Stanley Healthcare Conference, recently promoted CSO Francis Cuss spoke about Bristol’s plans to test a combination of Yervoy and nivolumab in a variety of tumor types. The pharma’s near-term goals also center on label expansion for Eliquis and filing the first all-oral combination regimen for hepatitis C in Japan.
You may also be interested in...
As Eliquis Sales Lag, Bristol/Pfizer Take Action
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.